These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 21331558)

  • 1. Extended anticoagulation for unprovoked venous thromboembolism: a majority of patients should be treated.
    Kearon C
    J Thromb Thrombolysis; 2011 Apr; 31(3):295-300. PubMed ID: 21331558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study.
    Kyrle PA; Kammer M; Eischer L; Weltermann A; Minar E; Hirschl M; Heinze G; Eichinger S
    J Thromb Haemost; 2016 Dec; 14(12):2402-2409. PubMed ID: 27696701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
    Marik PE; Cavallazzi R
    PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism.
    Kearon C; Akl EA
    Blood; 2014 Mar; 123(12):1794-801. PubMed ID: 24497538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism.
    Jiménez D; Díaz G; Marín E; Vidal R; Sueiro A; Yusen RD
    Thromb Haemost; 2006 Mar; 95(3):562-6. PubMed ID: 16525588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prolongation of anti vitamin K treatment for 18 months versus placebo after 6 months treatment of a first episode of ideopathic pulmonary embolism: a mutlicentre, randomised double blind trail. The PADIS-EP Trial].
    Couturaud F; Pernod G; Pison C; Mismetti P; Sanchez O; Meyer G; Parent F; Girard P; Simonneau G; Drouet L; Gueret P; Jego P; Delaval P; Duhamel E; Gruel Y; Delahousse B; Regina S; Pottier P; Connaud J; Lecomte F; Provost K; Vilmans N; Gosset X; Bura-Rivière A; Meach G; Lacut K; Bosson JL; Guillot K; Mottier D; Leroyer C
    Rev Mal Respir; 2008 Sep; 25(7):885-93. PubMed ID: 18946418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thirteen-year trend in the persistence with vitamin K antagonists for venous thromboembolism in the UK: a cohort study.
    Martinez C; Katholing A; Folkerts K; Rietbrock S
    Curr Med Res Opin; 2018 Nov; 34(11):1985-1990. PubMed ID: 29798688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Algorithmic Approach to Management of Venous Thromboembolism.
    Dhakal P; Gundabolu K; Bhatt VR
    Clin Appl Thromb Hemost; 2017 Sep; 23(6):511-517. PubMed ID: 27268941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of DVT: how long is enough and how do you predict recurrence.
    Agnelli G; Becattini C
    J Thromb Thrombolysis; 2008 Feb; 25(1):37-44. PubMed ID: 17906973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
    Robertson L; Yeoh SE; Ramli A
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study.
    Kearon C; Spencer FA; O'Keeffe D; Parpia S; Schulman S; Baglin T; Stevens SM; Kaatz S; Bauer KA; Douketis JD; Lentz SR; Kessler CM; Moll S; Connors JM; Ginsberg JS; Spadafora L; Julian JA;
    Ann Intern Med; 2015 Jan; 162(1):27-34. PubMed ID: 25560712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism.
    Kovacs MJ; Kahn SR; Wells PS; Anderson DA; Chagnon I; LE Gal G; Solymoss S; Crowther M; Perrier A; Ramsay T; Betancourt MT; White RH; Vickars L; Rodger MA
    J Thromb Haemost; 2010 Sep; 8(9):1926-32. PubMed ID: 20561184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual vein thrombosis and serial D-dimer for the long-term management of patients with deep venous thrombosis.
    Prandoni P; Vedovetto V; Ciammaichella M; Bucherini E; Corradini S; Enea I; Cosmi B; Mumoli N; Visonà A; Barillari G; Bova C; Quintavalla R; Zanatta N; Pedrini S; Villalta S; Camporese G; Testa S; Parisi R; Becattini C; Cuppini S; Pengo V; Palareti G;
    Thromb Res; 2017 Jun; 154():35-41. PubMed ID: 28407492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.
    Prandoni P; Noventa F; Ghirarduzzi A; Pengo V; Bernardi E; Pesavento R; Iotti M; Tormene D; Simioni P; Pagnan A
    Haematologica; 2007 Feb; 92(2):199-205. PubMed ID: 17296569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of venous thromboembolism.
    Wells PS; Forgie MA; Rodger MA
    JAMA; 2014 Feb; 311(7):717-28. PubMed ID: 24549552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
    Prandoni P; Barbar S; Milan M; Vedovetto V; Pesavento R
    Eur J Intern Med; 2014 Jan; 25(1):25-30. PubMed ID: 24120221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis.
    Khan F; Tritschler T; Kimpton M; Wells PS; Kearon C; Weitz JI; Büller HR; Raskob GE; Ageno W; Couturaud F; Prandoni P; Palareti G; Legnani C; Kyrle PA; Eichinger S; Eischer L; Becattini C; Agnelli G; Vedovati MC; Geersing GJ; Takada T; Cosmi B; Aujesky D; Marconi L; Palla A; Siragusa S; Bradbury CA; Parpia S; Mallick R; Lensing AWA; Gebel M; Grosso MA; Shi M; Thavorn K; Hutton B; Le Gal G; Rodger M; Fergusson D
    J Thromb Haemost; 2021 Nov; 19(11):2801-2813. PubMed ID: 34379859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of major bleeding during extended oral anticoagulation in patients with first unprovoked venous thromboembolism: a systematic review and meta-analysis protocol.
    Khan F; Kimpton M; Tritschler T; Le Gal G; Hutton B; Fergusson DA; Rodger MA
    Syst Rev; 2019 Oct; 8(1):245. PubMed ID: 31661033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
    Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Pinede L, Ninet J, Duhaut P et al for the Investigators of the 'Durée Optimale du Traitement Antivitamines K' (DOTAVK) study. Circulation 2001; 103: 2453-60.
    Anand SS
    Vasc Med; 2001 Nov; 6(4):269-70. PubMed ID: 11958396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.